S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon

NewAmsterdam Pharma (NAMS) Institutional Ownership

$19.93
+0.49 (+2.52%)
(As of 04/19/2024 ET)

Institutional Ownership Changes (13F Filings) for NewAmsterdam Pharma (NASDAQ:NAMS)

Current
Institutional Ownership
Percentage
89.89%
Number of
Institutional Buyers
(last 12 months)
19
Total
Institutional Inflows
(last 12 months)
$268.88M
Number of
Institutional Sellers
(last 12 months)
2
Total
Institutional Outflows
(last 12 months)
$245.27K
Get NAMS Insider Trade Alerts

Want to know when executives and insiders are buying or selling NewAmsterdam Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

NAMS Institutional Buying and Selling by Quarter

NewAmsterdam Pharma Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
4/10/2024 Yarbrough Capital LLC23,960$567K0.0%N/A0.027%
3/7/2024Fcpm Iii Services B.V.11,831,461$132.16M39.2%N/A14.373%
3/1/2024Goldman Sachs Group Inc.1,384,321$15.46M0.0%N/A1.682%
2/15/2024Opaleye Management Inc.265,388$2.96M0.8%N/A0.325%
2/15/2024Parkman Healthcare Partners LLC300,750$3.36M0.5%+20.8%0.369%
2/15/2024Citadel Advisors LLC21,046$235K0.0%-33.0%0.026%
2/14/2024Royal Bank of Canada10,875$121K0.0%+987.5%0.013%
2/13/2024Goldman Sachs Group Inc.1,384,321$15.46M0.0%N/A1.697%
2/1/2024Wolverine Asset Management LLC8,694$97K0.0%+197.2%0.011%
11/15/2023Affinity Asset Advisors LLC125,000$1.16M0.3%+25.0%0.153%
11/14/2023Schonfeld Strategic Advisors LLC64,700$598K0.0%+12.9%0.079%
11/13/2023Wolverine Asset Management LLC2,925$27K0.0%N/A0.004%
8/21/2023Affinity Asset Advisors LLC100,000$1.19M0.4%N/A0.123%
8/15/2023RA Capital Management L.P.9,000,000$107.01M2.0%+125.0%11.035%
8/15/2023Bain Capital Life Sciences Investors LLC10,473,913$124.54M12.8%+26.2%12.842%
8/14/2023Schonfeld Strategic Advisors LLC57,300$681K0.0%+90.4%0.070%
8/14/2023Marshall Wace LLP25,361$302K0.0%N/A0.031%
8/11/2023Geode Capital Management LLC25,768$306K0.0%+38.8%0.032%
8/11/2023JPMorgan Chase & Co.11,463$136K0.0%-48.8%0.014%
8/10/2023Monashee Investment Management LLC95,000$1.13M0.3%N/A0.116%
8/4/2023Maven Securities LTD25,000$297K0.0%N/A0.031%
7/19/2023Medicxi Ventures Management Jersey Ltd2,869,565$34.12M9.6%+43.5%3.518%
7/14/2023Venture Visionary Partners LLC10,000$119K0.0%N/A0.012%
5/18/2023JPMorgan Chase & Co.22,367$301K0.0%+1,929.7%0.126%
5/16/2023Geode Capital Management LLC18,559$249K0.0%N/A0.105%
5/15/2023Schonfeld Strategic Advisors LLC30,100$399K0.0%N/A0.170%
5/9/2023GMT Capital Corp1,083,800$14.37M0.6%+8.4%6.106%
5/8/2023Wolverine Asset Management LLC4,819$64K0.0%N/A0.027%
2/14/2023RA Capital Management L.P.4,000,000$43.60M0.9%N/A22.535%
2/14/2023Alyeska Investment Group L.P.200,000$1.89M0.0%N/A1.127%
2/3/2023Frazier Life Sciences Management L.P.9,341,551$101.82M6.3%N/A52.628%
2/3/2023GMT Capital Corp1,000,000$10.90M0.5%N/A5.634%
1/31/2023Medicxi Ventures Management Jersey Ltd2,000,000$21.80M9.2%N/A11.268%
(Data available from 1/1/2016 forward)

NAMS Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of NAMS shares?

During the previous two years, 22 institutional investors and hedge funds held shares of NewAmsterdam Pharma. The most heavily invested institutionals were Fcpm Iii Services B.V. ($132.16M), Bain Capital Life Sciences Investors LLC ($124.54M), RA Capital Management L.P. ($107.01M), Frazier Life Sciences Management L.P. ($101.82M), Medicxi Ventures Management Jersey Ltd ($34.12M), Goldman Sachs Group Inc. ($15.46M), and GMT Capital Corp ($14.37M).Learn more on NAMS's institutional investors.

What percentage of NewAmsterdam Pharma stock is owned by institutional investors?

89.89% of NewAmsterdam Pharma stock is owned by institutional investors. Learn more on NAMS's institutional investor holdings.

Which institutional investors have been buying NewAmsterdam Pharma stock?

Of the 21 institutional investors that purchased NewAmsterdam Pharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Fcpm Iii Services B.V. ($11.83M), Frazier Life Sciences Management L.P. ($9.34M), RA Capital Management L.P. ($9M), Medicxi Ventures Management Jersey Ltd ($2.87M), Goldman Sachs Group Inc. ($2.77M), Bain Capital Life Sciences Investors LLC ($2.17M), and GMT Capital Corp ($1.08M).

How much institutional buying is happening at NewAmsterdam Pharma?

Institutional investors have bought a total of 40,025,488 shares in the last 24 months. This purchase volume represents approximately $449.18M in transactions.

Which NewAmsterdam Pharma major shareholders have been selling company stock?

The following institutional investors have sold NewAmsterdam Pharma stock in the last 24 months: JPMorgan Chase & Co. ($10.90K), and Citadel Advisors LLC ($10.35K).

How much institutional selling is happening at NewAmsterdam Pharma?

Institutional investors have sold a total of 21,255 shares in the last 24 months. This volume of shares sold represents approximately $245.27K in transactions.


This page (NASDAQ:NAMS) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners